Mamie Z. Li

Mamie Z. Li

Auto-generated profile, based on publicly available information

Mamie Z. Li

Department of Genetics, Harvard Medical School, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2020 in Science
Verified
Journal Article
Open access
PDF file
ESEllen Shrock
Ellen Shrock
EFEric Fujimura
Eric Fujimura
TKTomasz Kula
Tomasz Kula
RTRichard T. Timms
Richard T. Timms
ILI-Hsiu Lee
I-Hsiu Lee
SEStephen J. Elledge
Stephen J. Elledge
Profiling coronaviruses: Among the coronaviruses that infect humans, four cause mild common colds, whereas three others, including the currently circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), result in severe infections. Shrock et al. used a technology known as VirScan to probe the antibody repertoires of hundreds of coronavirus disease 2019 (COVID-19) patients and pre–COVID-19 era controls. They identified hundreds of antibody targets, including several antibody epitopes shared by the mild and severe coronaviruses and many specific to SARS-CoV-2. A machine-learning model accurately classified patients infected with SARS-CoV-2 and guided the design of an assay for rapid SARS-CoV-2 antibody detection. The study also looked at how the antibody response and viral exposure history differ in patients with diverging outcomes, which could inform the production of improved vaccine and antibody therapies. Science , this issue p. eabd4250

17 September 2021 in Science
Verified
Journal Article
Closed access
TMTimothy D. Martin
Timothy D. Martin
RPRupesh S. Patel
Rupesh S. Patel
DCDanielle R. Cook
Danielle R. Cook
MCMei Yuk Choi
Mei Yuk Choi
APAjinkya Patil
Ajinkya Patil
SEStephen J. Elledge
Stephen J. Elledge
Defining tumor cell immune evasion: Mouse models used to study cancer often lack a full immune system, allowing implantation of human tumors into the mice. By contrast, naturally evolving tumors must contend with a fully functional immune system and its destruction of some of the cells (see the Perspective by Ho and Wood). Two groups now report studies on mouse models with a fully intact immune system. Martin et al . started with preexisting murine tumor cell lines and examined their continued evolution in vivo, whereas Del Poggetto et al . examined the development of new pancreatic tumors in the context of inflammation, as is often seen in human patients. In each study, the authors found that the immune system exerted a selective pressure on cells that would give rise to tumors, promoting the survival of those that had lost expression of tumor suppressor genes or activated a specific oncogene. The findings suggest a major role for the immune system in driving tumor evolution across multiple types of cancer. —YN

7 April 2023 in Science
Verified
Journal Article
Open access
ESEllen L. Shrock
Ellen L. Shrock
RTRichard T. Timms
Richard T. Timms
TKTomasz Kula
Tomasz Kula
EMElijah L. Mena
Elijah L. Mena
AWAnthony P. West
Anthony P. West
SEStephen J. Elledge
Stephen J. Elledge
Despite the vast diversity of the antibody repertoire, infected individuals often mount antibody responses to precisely the same epitopes within antigens. The immunological mechanisms underpinning this phenomenon remain unknown. By mapping 376 immunodominant “public epitopes” at high resolution and characterizing several of their cognate antibodies, we concluded that germline-encoded sequences in antibodies drive recurrent recognition. Systematic analysis of antibody-antigen structures uncovered 18 human and 21 partially overlapping mouse germline-encoded amino acid–binding (GRAB) motifs within heavy and light V gene segments that in case studies proved critical for public epitope recognition. GRAB motifs represent a fundamental component of the immune system’s architecture that promotes recognition of pathogens and leads to species-specific public antibody responses that can exert selective pressure on pathogens.

11 March 2021 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
SKSushil Kumar
Sushil Kumar
ZZZexian Zeng
Zexian Zeng
ABArchis Bagati
Archis Bagati
RTRong En Tay
Rong En Tay
LSLionel A. Sanz
Lionel A. Sanz
KWKai W. Wucherpfennig
Kai W. Wucherpfennig
A number of cancer drugs activate innate immune pathways in tumor cells but unfortunately also compromise antitumor immune function. We discovered that inhibition of CARM1, an epigenetic enzyme and cotranscriptional activator, elicited beneficial antitumor activity in both cytotoxic T cells and tumor cells. In T cells, Carm1 inactivation substantially enhanced their antitumor function and preserved memory-like populations required for sustained antitumor immunity. In tumor cells, Carm1 inactivation induced a potent type 1 interferon response that sensitized resistant tumors to cytotoxic T cells. Substantially increased numbers of dendritic cells, CD8 T cells, and natural killer cells were present in Carm1-deficient tumors, and infiltrating CD8 T cells expressed low levels of exhaustion markers. Targeting of CARM1 with a small molecule elicited potent antitumor immunity and sensitized resistant tumors to checkpoint blockade. Targeting of this cotranscriptional regulator thus offers an opportunity to enhance immune function while simultaneously sensitizing resistant tumor cells to immune attack. Significance: Resistance to cancer immunotherapy remains a major challenge. Targeting of CARM1 enables immunotherapy of resistant tumors by enhancing T-cell functionality and preserving memory-like T-cell populations within tumors. CARM1 inhibition also sensitizes resistant tumor cells to immune attack by inducing a tumor cell–intrinsic type 1 interferon response. This article is highlighted in the In This Issue feature, p. 1861

1 April 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
WMWilliam R. Morgenlander
William R. Morgenlander
SHStephanie N. Henson
Stephanie N. Henson
DMDaniel R. Monaco
Daniel R. Monaco
ACAthena Chen
Athena Chen
KLKirsten Littlefield
Kirsten Littlefield
HLH. Benjamin Larman
H. Benjamin Larman
SARS-CoV-2 (CoV2) antibody therapies, including COVID-19 convalescent plasma (CCP), monoclonal antibodies, and hyperimmune globulin, are among the leading treatments for individuals with early COVID-19 infection. The functionality of convalescent plasma varies greatly, but the association of antibody epitope specificities with plasma functionality remains uncharacterized. We assessed antibody functionality and reactivities to peptides across the CoV2 and the 4 endemic human coronavirus (HCoV) genomes in 126 CCP donations. We found strong correlation between plasma functionality and polyclonal antibody targeting of CoV2 spike protein peptides. Antibody reactivity to many HCoV spike peptides also displayed strong correlation with plasma functionality, including pan-coronavirus cross-reactive epitopes located in a conserved region of the fusion peptide. After accounting for antibody cross-reactivity, we identified an association between greater alphacoronavirus NL63 antibody responses and development of highly neutralizing antibodies against CoV2. We also found that plasma preferentially reactive to the CoV2 spike receptor binding domain (RBD), versus the betacoronavirus HKU1 RBD, had higher neutralizing titer. Finally, we developed a 2-peptide serosignature that identifies plasma donations with high anti-spike titer, but that suffer from low neutralizing activity. These results suggest that analysis of coronavirus antibody fine specificities may be useful for selecting desired therapeutics and understanding the complex immune responses elicited by CoV2 infection.

19 October 2021 in Cell Reports Medicine
Verified
Journal Article
Open access
GCGenghao Chen
Genghao Chen
ESEllen L. Shrock
Ellen L. Shrock
MLMamie Z. Li
Mamie Z. Li
JSJonathan M. Spergel
Jonathan M. Spergel
KNKari C. Nadeau
Kari C. Nadeau
SEStephen J. Elledge
Stephen J. Elledge
Peanut allergy can result in life-threatening reactions and is a major public health concern. Oral immunotherapy (OIT) induces desensitization to food allergens through administration of increasing amounts of allergen. To dissect peanut-specific immunoglobulin E (IgE) and IgG responses in subjects undergoing OIT, we have developed AllerScan, a method that leverages phage-display and next-generation sequencing to identify the epitope targets of peanut-specific antibodies. We observe a striking diversification and boosting of the peanut-specific IgG repertoire after OIT and a reduction in pre-existing IgE levels against individual epitopes. High-resolution epitope mapping reveals shared recognition of public epitopes in Ara h 1, 2, 3, and 7. In individual subjects, OIT-induced IgG specificities overlap extensively with IgE and exhibit strikingly similar antibody footprints, suggesting related clonal lineages or convergent evolution of peanut-specific IgE and IgG B cells. Individual differences in epitope recognition identified via AllerScan could inform safer and more effective personalized immunotherapy.